12.11.25 -- Formulation And Delivery Considerations For Cell And Gene Therapies

Effective cell concentration and buffer exchange are crucial in MSC biomanufacturing for safety and efficacy. Compare the trade-offs of centrifugation, filtration, and elutriation to optimize your process.

Learn about tangential flow filtration (TFF), typical TFF system configurations, ultrafiltration fundamentals, applications, system selection considerations, and more.

CAR-T cell therapy shows unprecedented efficacy in targeting cancer. Explore a device that simplifies the manufacturing process and enables automated CAR-T cell generation to ensure quality control and phenotyping.

Unlock insights into sterile gas filtration challenges in bioprocessing. Watch this on-demand session to learn optimization strategies for critical applications and improved filter performance.

Drug shortages have increased the burden on compounding pharmacies. Robotics and automation can streamline processes, improve accuracy, and ensure quality to address challenges faced by these facilities.

Low-shear, closed-system media exchange in iPSC differentiation is vital for scalability. This study compares automated centrifugation to gravity sedimentation, showing equivalent or superior differentiation outcomes.

From tumor resection to therapy delivery, there are a number of hurdles at each stage of your TIL therapy manufacturing workflow. Here, we address key challenges at each stage of the workflow.

Assimilate how a system that uses a gentle elutriation process to give manufacturers a cleaner cell population to begin cell therapy production processes such as CAR-T.

A new chemically defined fed-batch bioprocess medium simplifies hMSC-EV production, increasing yields by 2-4x while maintaining EV quality across donors and tissue types in scalable GMP-compatible environments.

See strategies for optimizing AAV gene therapy manufacturing. Discover solutions for scaling production, enhancing purification, and improving analytical methods to accelerate therapeutic development.

A chemically defined T cell workflow improves reproducibility and supports robust expansion in both static and bioreactor scale-up systems, while allowing for the elimination of the post-thaw wash step.

Evaluate how a modular, functionally closed, end-to-end solution streamlines and de-risks the manufacture of autologous CAR T-cell therapies, improving consistency, scalability, and time-to-patient.

The success of this experiment shows how the integration of Process Analytical Technology probes into bioreactors can enhance process understanding and enable precise bioprocess monitoring and control.

Current "end-to-end" automation often forces sacrifices in cell therapy manufacturing, but a strategy integrating specialized technologies for key bottlenecks is now aiming to improve efficiency.